Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

lorlatinib

- PMLiVE

Keytruda ups survival in lung cancer, misses secondary target

Data shows Keytruda fails to beat BMS' Opdivo

EU flag

CHMP October meeting gives recommendations for Pfizer and MSD

But the regulatory advisors sound note ofcaution on Biogen’s Tecfidera

- PMLiVE

GSK and J&J back new UK dementia discovery fund

Pharma giants collaborate with government to find new treatments

- PMLiVE

Pfizer’s investigational leukaemia drug wins breakthrough status

Puts inotuzumab ozogamacin in line for development incentives

- PMLiVE

FDA turns down Pfizer’s Xeljanz in psoriasis

USregulator dampens the firm's hope of expanding arthritis drug's uses

- PMLiVE

Boehringer takes a mega pair of lungs on tour

Welshawareness campaign aims help tackle the country's poor cancer record

- PMLiVE

BMS recruits Jack Huston for European Lung cancer campaign

TheBoardwalk Empire actor will work with the firm on an awareness drive

- PMLiVE

FDA fast-tracks Merck/Pfizer’s rare skin cancer drug avelumab

Comes a month after drug was given orphan status

- PMLiVE

Merck gets lung cancer OK for Keytruda in US

Highlights increased understanding of molecular processes in cancer

- PMLiVE

Pfizer launches first self-injectable contraceptive in UK

New option for female contraception hits UK

- PMLiVE

Amgen and Allergan close on Avastin biosimilar filing

ABP 215 matches reference drug in study

Bristol-Myers Squibb (BMS) building

Opdivo a breakthrough in kidney cancer, says FDA

BMSmoves closer to US approval of its checkpoint inhibitor cancer immunotherapy

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links